A Phase 3 interventional study of Atogepant and Placebo for Atogepant in Migraine, sponsored by AbbVie. Completed at 149 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.
Among the 21 studies testing atogepant in Migraine Disorders, this one has the largest enrollment, is the only one that started in 2024, is one of 15 in phase 3, and was the 16th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Canada, Denmark and 8 more countries
Ages 12–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
Konrad Peter Weber · Sites in Switzerland
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 16 · Phase 4 4
First in 2016; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,158 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 468 across the 21 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 5 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one has the largest enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2024, is one of 30 in phase 3, and was the 46th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing atogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
A migraine attack is a moderate or severe headache that usually occurs on one side of the head and is often accompanied by throbbing, sensitivity to light, sensitivity to sound, nausea, or other symptoms. The main goal of the study is to see if atogepant is effective, safe, and well-tolerated in treating migraine attacks quickly.
Atogepant is a medicine currently approved for the preventive treatment of migraine in adults and has been shown to be effective and well tolerated when taken daily to prevent migraine attacks. This study includes double-blind phase means that neither the participants nor the study doctors know who is given which study treatment (atogepant or placebo) followed by an open-label phase meaning that both participants and study doctors know which study treatment is given. All participants will receive atogepant during the open-label part of the study. This study will include 1300 participants aged 18-75 years with a history of migraine at approximately 160 sites across the world.
All participants will receive both atogepant and placebo to treat qualifying migraines. At the start of the study, participants will be randomized to 1 of 4 dosing sequences to determine when they will receive atogepant and when they will receive placebo during the study. After treating 4 qualifying migraine attacks, participants will receive open-label atogepant for any additional migraine attacks they have until the end of the study (Week 24).
There may be a bigger responsibility for participants in this study than there would be in participants receiving standard of care treatment. participants will attend regular visits during the study at a hospital or clinic, as well as telephone visits, and the effects of treatment will be checked by completion of questionnaires in an electronic diary, medical assessments, blood tests, and checking for side effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive both atogepant and placebo to treat qualifying migraines.
Drug: Atogepant · Drug: Placebo for Atogepant
Participants will receive both atogepant and placebo to treat qualifying migraines.
Drug: Atogepant · Drug: Placebo for Atogepant
Participants will receive both atogepant and placebo to treat qualifying migraines.
Drug: Atogepant · Drug: Placebo for Atogepant
Participants will receive both atogepant and placebo to treat qualifying migraines.
Drug: Atogepant · Drug: Placebo for Atogepant
Oral Tablet
Also known as: Qulipta, Aquipta
Oral Tablet
Percentage of Participants Achieving Pain Freedom at 2 Hours After the Double-Blind (DB) Dose for the First Attack
Pain freedom is defined as a reduction in headache severity from moderate/severe at baseline (predose) to no pain.
Time frame: Approximately 16 Weeks
Percentage of Participants With Absence of Most Bothersome Migraine-associated Symptom (MBS) at 2 Hours After the Double-Blind (DB) Dose for the First Attack
Percentage of Participants With Absence of Most Bothersome Migraine-associated Symptom (MBS) will be assessed.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Pain Relief at 2 Hours After the Double-Blind (DB) Dose for the First Attack
Pain relief is defined as the reduction of a moderate/severe migraine headache at baseline \[predose\] to a mild headache or to no headache.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Sustained Pain Relief From 2 to 24 Hours After DB Dose for the First Attack
Sustained pain relief is defined as pain relief at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a moderate/severe headache from 2 to 24 hours.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Sustained Pain Relief From 2 to 48 Hours After DB Dose for the First Attack
Sustained pain relief is defined as pain relief at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a moderate/severe headache from 2 to 24 hours.
Time frame: Approximately 16 Weeks
Percentage of Participants With Use of Rescue Medication Within 24 Hours After DB Dose for the First Attack
Percentage of participants with use of rescue medication within 24 hours after the DB dose for the first attack will be assessed.
Time frame: Approximately 16 Weeks
Percentage of Participants With Ability to Function Normally at 2 Hours After DB Dose for the First Attack
Percentage of participants with ability to function normally at 2 hours after the DB dose for the first attack will be assessed.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Sustained Pain Freedom From 2 to 24 Hours After DB Dose for the First Attack
Sustained pain freedom is defined as pain freedom at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a mild/moderate/severe headache from 2 to 24 hours.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Sustained Pain Freedom From 2 to 48 Hours After DB Dose for the First Attack
Sustained pain freedom is defined as pain freedom at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a mild/moderate/severe headache from 2 to 24 hours.
Time frame: Approximately 16 Weeks
Percentage of Participants With Absence of Photophobia at 2 Hours After the DB Dose for the First Attack
Photophobia is defined as sensitivity to light.
Time frame: Approximately 16 Weeks
Percentage of Participants With Absence of Phonophobia at 2 Hours After the DB Dose for the First Attack
Phonophobia is defined as sensitivity to sound.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Pain Freedom at 8 Hours After the DB Dose for the First Attack
Pain freedom is defined as a reduction in headache severity from moderate/severe at baseline (predose) to no pain.
Time frame: Approximately 16 Weeks
Percentage of Participants With Ability to Function Normally at 8 Hours After DB Dose for the First Attack
Percentage of participants with ability to function normally at 8 hours after the DB dose for the first attack will be assessed.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Pain Relief at 1 Hour After the Double-Blind (DB) Dose for the First Attack
Pain relief is defined as the reduction of a moderate/severe migraine headache at baseline \[predose\] to a mild headache or to no headache.
Time frame: Approximately 16 Weeks
Percentage of Participants With Absence of Nausea at 2 Hours After the Double-Blind (DB) Dose for the First Attack
Percentage of participants with absence of nausea at 2 hours after the DB dose for the first attack.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Pain Relief at 30 Minutes After the Double-Blind (DB) Dose for the First Attack
Pain relief is defined as the reduction of a moderate/severe migraine headache at baseline \[predose\] to a mild headache or to no headache.
Time frame: Approximately 16 Weeks
Percentage of Participants With Ability to Function Normally at 1 Hour After DB Dose for the First Attack
Percentage of participants with ability to function normally at 1 hour after the DB dose for the first attack will be assessed.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Pain Freedom at 2 Hours After Receiving DB Atogepant for at least 2 out of 3 Attacks
Pain freedom is defined as a reduction in headache severity from moderate/severe at baseline (predose) to no pain.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Pain Relief at 2 Hours After Receiving Double-Blind (DB) Atogepant for at least 2 out of 3 Attacks
Pain relief is defined as the reduction of a moderate/severe migraine headache at baseline \[predose\] to a mild headache or to no headache.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Sustained Pain Freedom From 2 to 24 Hours After Receiving DB Atogepant for at least 2 out of 3 Attacks
Sustained pain freedom is defined as pain freedom at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a mild/moderate/severe headache from 2 to 24 hours.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Sustained Pain Freedom From 2 to 48 Hours After Receiving DB Atogepant for at least 2 out of 3 Attacks
Sustained pain freedom is defined as pain freedom at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a mild/moderate/severe headache from 2 to 24 hours.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Sustained Pain Relief From 2 to 24 Hours After Receiving DB Atogepant for at least 2 out of 3 Attacks
Sustained pain relief is defined as pain relief at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a moderate/severe headache from 2 to 24 hours.
Time frame: Approximately 16 Weeks
Percentage of Participants Achieving Sustained Pain Relief From 2 to 48 Hours After Receiving DB Atogepant for at least 2 out of 3 Attacks
Sustained pain relief is defined as pain relief at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a moderate/severe headache from 2 to 24 hours.
Time frame: Approximately 16 Weeks
Showing the first 100 of 149 sites across 15 countries. Choose a country and city above to see the rest.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Mar 2024 to primary completion in Jul 2025, 15 months.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 15 months is below that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atogepant